SOLICITATION NOTICE
B -- Ovation Pico WTA System
- Notice Date
- 5/11/2011
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-(HL)-2011-173-DDC
- Archive Date
- 5/31/2011
- Point of Contact
- Deborah - Coulter, Phone: (301) 435-0368
- E-Mail Address
-
dc143b@nih.gov
(dc143b@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The COAC Services Branch, Office of Acquisitions, DERA, National Heart, Lung, and Blood Institute (NHLBI), NIH, for the Framingham Heart Study under the NHLBI, Division of Intramural Research (DIR) Center for Population Studies, intends to award a purchase order on a sole source basis for the purchase of custom kit containing Ovation Pico WTA System Encore Biotin module, and Exon Module ~96rxn. The reference number: NHLBI-CSB-(HL)-2011-173-DDC. Background: Cardiovascular disease (CVD) is the leading cause of death and serious illness in the United States. In 1948, the Framingham Heart Study -- under the direction of the National Heart Institute (now known as the National Heart, Lung, and Blood Institute; NHLBI) -- embarked on an ambitious project in health research. At the time, little was known about the general causes of heart disease and stroke, but the death rates for CVD had been increasing steadily since the beginning of the century and had become an American epidemic. The objective of the Framingham Heart Study was to identify the common factors or characteristics that contribute to CVD by following its development over a long period of time in a large group of participants who had not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The Framingham Heart Study continues to make important scientific contributions by enhancing its research capabilities and capitalizing on its inherent resources. New diagnostic technologies, such as echocardiography (an ultrasound examination of the heart), carotid-artery ultrasound, bone densitometry (for monitoring osteoporosis), and computerized tomography of the coronary arteries, are evaluated and integrated into ongoing protocols. Purpose: This acquisition is for the purpose of procurement of Nugen reagents, reagents necessary to process paxgene RNA samples to conduct gene expression profiling. The project will involve the procurement of reagents for 2400 samples. Period of Performance: May 16, 2011- Jul 31, 2011 Contractor Requirements: A. Contractor shall provide the reagents and enzymes to process blood samples which would be used on Affymetrix gene chips. B. The Contractor shall provide the necessary technical support during the sample processing step and the required internal controls for use as a quality control measure. II. Government Responsibilities A. NHLBI will inspect each kit and determine if the supplied enzymes and buffers are adequate for processing samples. III. Reporting Requirements and Deliverables A. Prepared cDNA target using the Nugen kit would be QCed in NHLBI for concentration and integrity using a spectrophotometer and bioanalyzer. B. Samples that have passed the QC would be hybridized to gene chips for further analysis. Program Management and Control Requirements No special management or control systems are required under this contract. Items to be purchased: Item Number: 9010 Custom kit containing Ovation Pico WTA System Encore Biotin module, and Exon Module~96rxn, quantity 25 each The sole source determination is based on the fact the National Institute of Health (NIH) is the nation's medical research agency and the primary Federal agency conducting and supporting making medical discoveries that improve people's health and save lives. The Framingham SABRe CVD Initiative Study under the National Heart, Lung, and Blood Institute (NHLBI) of NIH is conducting a study to identify the common factors or characteristics that contribute to Cardiovascular Disease (CVD) by following the development over a long period of time in a large group of participants who have not yet developed overt symptoms of CVD or suffered a heart attack or stroke. The study will expand research to include genomic biomarkers in CVD and will collaborate with other leading researchers across the country and world on various projects, such as, stroke and dementia, osteoporosis and arthritis and genetic patterns of common diseases. The collaborative study in biomarkers will analyze 7000 samples on Human Exon arrays to identify different expressed genes and associated alternative splicing events using the Affymetrix Platform. Specifically, the study will identify genes with altered expressions in heart, lung, and blood disorders and in a parallel study alternative splicing events during the disease process. The studies will be conducted in phases and the intent is to analyze gene expression in WBCs blood samples (n=2400) from Framingham Heart Study Offspring participants. Therefore, NHLBI is in need of NuGEN Technologies WT-Ovation Pico RNA Amplification System Automation to amplify 50 ng of total RNA from whole blood. The WT-Ovation Exon Module (60rx) will be used in preparation of labeled cDNA target to hybridize to Exon genechips. NuGEN Technologies is the only company that manufacturers these reagents. The Ovation® System family of products is covered by U.S. Patent Nos. 6,692,918, 6,251,639 and 6,946,251, and other issued and pending US and international patents. These are the only reagents that are suitable for the existing affymetrix platform operated in the core facility and the reagents have been validated in the core lab. In order to maintain a high standard of quality and reproducibility of experiments while increasing data output, the reagents manufactured by NuGEN is of critical importance. The notice of intent is not a request for competitive proposals. Only one responsible source and no other supplies or services will satisfy agency requirements. Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology with size standard of 500 employees; the small business set-aside does apply for this requirement. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001) and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-50 (May 6, 2011). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by May 16, 2011, 7:30 am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-(HL)-2011-173-DDC/listing.html)
- Place of Performance
- Address: NIH, Framingham, Massachusetts, 01702, United States
- Zip Code: 01702
- Zip Code: 01702
- Record
- SN02445392-W 20110513/110511234634-9b6e21f4c08a83ef0ff875e141728b01 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |